Press release -

​Responding to Coronavirus - Vironova remains operational

Our commitment during the Covid-19 - Control the controllables

Which in short can be summarized by :

  • Ensure the health and safety of our employees
  • Enable business by remote work for employees and remaining operational for our customers

As the coronavirus continues to spread globally, we wish to let you know that our first priority is the safety and well-being of our employees, clients, families and partners around the world. Thus, we have taken measures in order to do our part in trying to delay the spread of the virus and help flatten the curve.

Vironova AB has established a Health and Business Risk Mitigation Group, which is lead by the management team to represent our departments, to closely monitor the evolving internal and external situation. The Group is responsible for enacting measures that will ensure the safety of our employees and business continuity for our clients. Plans are in place to ensure that we can continue to deliver the highest possible level of quality service and execution under these unique circumstances. To maintain throughput in our GMP certified laboratory, our microscopist are now rotated and scheduled around 7-day work weeks.

Concerning our Swedish and international operations, a large percentage of our employees in Sweden are working from home in order to minimize physical contact, which also is the current recommendation from the Swedish authorities (Folkhälsomyndigheten). However, it is business as usual at Vironova via remote measures to remain fully operational. 

Please do not hesitate to reach out to your usual contact at Vironova if you have any questions or feel free to email me directly.

Our thoughts are with the people who have been affected by this and we appreciate the frontline healthcare workers, local communities and governments working to control COVID-19.


Sincerely

Mohammed Homman
CEO
Vironova AB

Topics

  • Medical research

Categories

  • em services
  • virus
  • vironova
  • covid-19
  • nanoparticles
  • biopharmaceuticals
  • influensa
  • läkemedel
  • minitem
  • coronavirus

Vironova is a Swedish biotechnology company providing comprehensive, hardware, software and services for the analysis of nanoparticles. Vironova revolutionizes access to transmission electron microscopy (TEM)-based image analysis in biopharmaceutical development. Our solution enables automated analyses for faster and better-informed decisions to secure robust bioprocessing and final product quality. Primarily in the gene therapy and vaccine market.

The Vironova offering comprises:

  • Cost effective, fast Electron Microscopy (EM) services enabled by the in-house developed Vironova Analyzing Software (VAS) designed for semi-automated nanoparticle analysis
  • Viral clearance testing performed in GLP and BSLIII certified laboratories
  • MiniTEM™, a bench-top Transmission Electron Microscope system designed for automated nanoparticle characterization. High-resolution images reveal particle morphologies that are transformed into accurate metrics.

Contacts

Josefina Nilsson

Press contact CEO